Response of other HCL patients to LMB-2. For patients no. 15 (A), 35 (B), and 32 (C), the concentrations of circulating WBCs (•) and HCL cells determined by FACS and morphology (○) are shown. Treatment days are shown (▿) for the indicated cycles. Patients no. 15 and 35 in (A) and (B) received LMB-2 at 30 and 40 μg/kg IV QOD × 3, respectively. Patient no. 32 received 1 dose of LMB-2 at 63 μg/kg on day 1. In (C), the Y-axis is depicted showing the log of the WBC and HCL counts to show the wide fluctuation in the counts after the first dose.